These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 20705397)

  • 41. Novel Treatment Options for Neuroendocrine Tumors.
    Kulke MH
    J Natl Compr Canc Netw; 2017 May; 15(5S):737-739. PubMed ID: 28515259
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Treatment of neuroendocrine tumors of the digestive tract].
    Wada I; Shimizu N; Seto Y
    Gan To Kagaku Ryoho; 2009 Oct; 36(10):1606-10. PubMed ID: 19838017
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hypoglycemia induced by long-acting somatostatin analogues in a patient with nonfunctional neuroendocrine tumor.
    Unek IT; Celtik A; Yener S; Yavuzsen T; Alacacioglu A; Cokmert S; Oztop I; Demirkan B; Dicle O; Sagol O; Bekis R; Yilmaz U
    J BUON; 2009; 14(1):135-8. PubMed ID: 19365885
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neuroendocrine tumors of the pancreas.
    Ehehalt F; Saeger HD; Schmidt CM; Grützmann R
    Oncologist; 2009 May; 14(5):456-67. PubMed ID: 19411317
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Introduction to a revised clinicopathological classification of neuroendocrine tumors of the gastroenteropancreatic tract.
    Rindi G; Capella C; Solcia E
    Q J Nucl Med; 2000 Mar; 44(1):13-21. PubMed ID: 10932598
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review.
    Pusceddu S; De Braud F; Festinese F; Bregant C; Lorenzoni A; Maccauro M; Milione M; Concas L; Formisano B; Leuzzi L; Mazzaferro V; Buzzoni R
    Future Oncol; 2015; 11(13):1947-59. PubMed ID: 26161929
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Therapy innovation for the treatment of pancreatic neuroendocrine tumors.
    Riccardi F; Rizzo M; Festino L; Ambrosio F; Molino C; Uomo G; Cartenì G
    Expert Opin Ther Targets; 2012 Apr; 16 Suppl 2():S91-102. PubMed ID: 22372544
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Somatostatin analogues for the treatment of gastro-entero-pancreatic neuroendocrine tumours].
    Uomo G; Germano D; Rabitti PG
    Minerva Endocrinol; 2001 Dec; 26(4):225-9. PubMed ID: 11782707
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms.
    Grozinsky-Glasberg S; Shimon I; Korbonits M; Grossman AB
    Endocr Relat Cancer; 2008 Sep; 15(3):701-20. PubMed ID: 18524947
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recent advances in the management of gastroenteropancreatic neuroendocrine tumors: insights from the 2017 ASCO Gastrointestinal Cancers Symposium.
    Iyer R; Phan AT; Boudreaux JP
    Clin Adv Hematol Oncol; 2017 Apr; 15 Suppl 4(4):1-24. PubMed ID: 28654022
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Future aspects of somatostatin-receptor-mediated therapy.
    Oberg K
    Neuroendocrinology; 2004; 80 Suppl 1():57-61. PubMed ID: 15477719
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors < 2 Centimeters.
    Faggiano A; Modica R; Lo Calzo F; Camera L; Napolitano V; Altieri B; de Cicco F; Bottiglieri F; Sesti F; Badalamenti G; Isidori AM; Colao A
    J Clin Endocrinol Metab; 2020 Jan; 105(1):. PubMed ID: 31586182
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The antiproliferative effect of somatostatin analogs: clinical relevance in patients with neuroendocrine gastro-entero-pancreatic tumours.
    Verslype C; Carton S; Borbath I; Delaunoit T; Demetter P; Demolin G; Hendlisz A; Pattyn P; Pauwels S; Peeters M; Roeyen G; Van Hootegem P; Van Laethem JL; Van Cutsem E
    Acta Gastroenterol Belg; 2009; 72(1):54-8. PubMed ID: 19402373
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Surgical treatment of non-functioning pancreatic islet cell tumors.
    Kouvaraki MA; Solorzano CC; Shapiro SE; Yao JC; Perrier ND; Lee JE; Evans DB
    J Surg Oncol; 2005 Mar; 89(3):170-85. PubMed ID: 15719379
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New pharmacologic therapies for gastroenteropancreatic neuroendocrine tumors.
    Lawrence B; Gustafsson BI; Kidd M; Modlin I
    Gastroenterol Clin North Am; 2010 Sep; 39(3):615-28. PubMed ID: 20951920
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors.
    Delaunoit T; Rubin J; Neczyporenko F; Erlichman C; Hobday TJ
    Mayo Clin Proc; 2005 Apr; 80(4):502-6. PubMed ID: 15819288
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The new classification of neuroendocrine tumors from the clinical viewpoint].
    Schürmann G; Senninger H
    Z Gastroenterol; 1996 Jun; 34(6):402-3. PubMed ID: 8767831
    [No Abstract]   [Full Text] [Related]  

  • 58. Biotherapies for GEP-NETs.
    Öberg K
    Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):833-41. PubMed ID: 23582922
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Systemic therapy for advanced pancreatic neuroendocrine tumors.
    Kulke MH
    Semin Oncol; 2013 Feb; 40(1):75-83. PubMed ID: 23391115
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Systemic therapy for advanced pancreatic neuroendocrine tumors: an update.
    Reidy-Lagunes DL
    J Natl Compr Canc Netw; 2012 Jun; 10(6):777-83. PubMed ID: 22679119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.